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Access to controlled medications is problematic in many countries, in spite of the objectives 
of the international substance control conventions. The review describes barriers for accessing 
medications and how to assess the adequacy of opioid analgesic consumption globally. As cur-
rent trends in consumption, it discusses the lack of progress of improving access and the threat 
of the false narrative that people who suffer moderate to severe pain are the cause of an epi-
demic of opioid intoxications. Finally, it questions the feasibility of an approach which requires 
large numbers of anaesthesiologist for treating chronic pain, and wonders what the effect of 
the COVID-19 pandemic on accessibility to controlled medications will be.
Keywords: Analgesics; Opioids; Pain Management; Health Policy; Needs Assessment
Introduction
Access to controlled medications is problematic in many countries, in spite of the objectives of the inter-
national substance control conventions, which are to ensure their medical and scientific availability while 
preventing non-medical use (United Nations Office on Drugs and Crime 2009a; United Nations Office on 
Drugs and Crime 2009b). 
Psychoactive substances are indicated for a number of conditions and diseases, including pain, anaesthe-
sia, opioid use disorder, dyspnoea, epilepsy, obstetric emergencies, and psychological crises. Moreover, other 
than many people think, it should be noticed that opioid analgesics are not needed for cancer pain or for 
palliative care only, but for a wide range of acute and chronic moderate and severe types of pain (Häuser et 
al. 2015; Moisset and Martinez 2016). The continuing under availability of opioid analgesics is widely docu-
mented (International Narcotics Control Board 1989; Seya et al. 2011; Cherny et al. 2013; Cleary et al. 2013; 
Duthey and Scholten 2014; Berterame et al. 2016; Knaul et al. 2018; Scholten et al. 2019; Scholten et al. 
2020). However, many other controlled medications are not readily available. For instance, affordable anti-
epileptics are often not available in developing countries, due to their classification as controlled substances 
(Milani and Scholten 2011).
In 2006, the World Health Organization estimated that in countries with low to non-existent access, each 
year tens of millions of patients are suffering without adequate pain treatment. These include 1 million 
end-stage HIV/AIDS patients, 5.5 million terminal cancer patients, 0.8 million patients suffering injuries, 
caused by accidents and violence, and furthermore, patients with chronic illnesses, patients recovering from 
surgery, women in labour (110 million births each year), and paediatric patients (World Health Organization 
2006). 
The Lancet Commission on Palliative Care and Pain Relief estimated that more than 61 million people 
experienced serious health-related suffering in 2015, including 25.5 million people who died, which is 
almost half of reported deaths worldwide. More than 80% of these people live in lower- or middle-income 
countries where access to basic palliative care and medicine-based pain relief is extremely limited or non-
existent (Knaul et al. 2018).
The number of people potentially not being treated for pain is much higher: in 2015, 5.7 billion people 
lived in countries where the per capita consumption of opioid analgesics is very or extremely low, and 
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another half a billion lived in countries for which no data were available, but which have so many similari-
ties to the former countries, that it is likely that their populations have no access either. This is a constant 
percentage of the world population and thus, with an increasing world population, the number of people 
potentially affected is increasing (Scholten et al. 2019; Scholten et al. 2020). 
Authorities around the world tend to overemphasise the importance of preventing non-medical use, while 
not paying attention to the importance of medical use. Non-medical use is perceived as an important prob-
lem, but the burden of disease from pain is at least 37 times larger than the burden of disease from sub-
stance use disorder (Scholten and Henningfield 2016a). 
The World Health Organization published policy guidelines (currently under revision, see below) in order 
to encourage policies that optimize the balance between the prevention of non-medical use and the acces-
sibility for medical purposes of controlled medications (World Health Organization 2010). The Pompidou 
Group of the Council of Europe published Guiding Principles focusing especially on access to pharmacologi-
cal treatment of opioid use disorder (Pompidou Group 2017).
Barriers for Accessing Controlled Medications
Reasons for low consumption levels vary by country. It is possible that opioids are not stocked by the phar-
macy (unavailable), that the doctor is not willing to prescribe, the pharmacy not willing to dispense, or 
the authorities prevent prescribing (inaccessible), or the medication can be too expensive (unaffordable). 
Regardless whether they are unavailable, inaccessible or unaffordable, in all three cases the patient will not 
be able to benefit pain relief (Scholten 2013). 
Low availability, low accessibility and low affordability can have a variety of causes, which need accurate 
analysis for improving the situation. Four categories of barriers can be distinguished: legislative and policy 
barriers, knowledge barriers, attitudes barriers, and economic barriers (World Health Organization 2010).
Legislative and policy barriers consist usually of too strict rules, often not contributing to the prevention 
of non-medical use, but effectively blocking rational medical use. One study analysed the legislation in 11 
countries in Eastern Europe and identified for each country between 22 and 128 rules that were a potential 
barrier. Between 6 and 76 rules related to prescribing and dispensing of opioid medications, and between 
15 and 102 related to access to opioid agonist treatment for treatment of opioid dependence (Vranken et al. 
2018). Such rules are often more perceived as a barrier by health-care professionals and other stakeholders, 
than by civil servants: 55–57% of health-care professionals rated excessive regulation and/or bureaucracy as 
having a major impact, against 20% of the policy makers (Vranken et al. 2019). The GOPI project identified 
undue regulation of opioid analgesics worldwide (Cherny et al. 2013).
Although most legislative barriers stem from national regulations, there is also one specific regulatory bar-
rier that originates from the Single Convention on Narcotic Drugs: the estimate system. It was introduced in 
1931 in analogy of the Soviet planning economy and later included in the Single Convention (Anonymous 
1931; United Nations Office on Drugs and Crime 2009b). The Single Convention requires that all countries 
submit an annual estimate for the amount of controlled substances they need. Without a sufficient esti-
mate submitted to the International Narcotics Control Board (INCB), other countries will refuse exporta-
tion to such a country. In spite of guidance developed by the World Health Organization (WHO) and INCB, 
many countries do not submit adequate estimates to INCB, leading to supply shortages again and again 
(International Narcotics Control Board and World Health Organization 2012).
Knowledge among health-care professionals is another problem for the use of controlled medications. 
Although the prescription of opioid analgesics is not difficult, due to the development of tolerance, there 
are a few peculiarities that prescribers need to know. The most important is how to safely increase the dos-
age on initiation of pain therapy (maximum increase 50% per 24 hours), and the other is how to decrease on 
cessation (taking from a few days after a brief episode of administration up to several months after chronic 
administration of long-acting opioids). Many prescribers do not know that initiation and cessation are dif-
ferent from most other medications, and many hand and textbooks do not provide this information either 
(Scholten 2012). This leads to potentially dangerous situations.
Low levels of pain management education were identified by a study in 11 Eastern European countries 
and another study that covered most of Europe (Radbruch et al. 2014; Briggs et al. 2015). The latter found 
very low numbers of study hours and even the absence of pain management in the curriculum of many 
medical schools. 
Also attitudes both among professionals and the lay population may lead to avoidance and refusal of ther-
apy that could benefit the patient. Often this has to do with the idea that ‘everybody will become dependent 
upon his/her first dosage’, even in situations where the problem of dependence is irrelevant (e.g. terminal 
disease) (Krakauer et al. 2010). However, two Cochrane reviews showed that there is no evidence that the risk 
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of developing a substance use disorder is justifying the withholding of opioid analgesics to people with pain 
(Minozzi, Amato and Davoli 2013) and that less than 1% of people to whom opioid analgesics are prescribed 
will develop dependence (Noble et al. 2010). Accurate information, therefore, can avoid inappropriate atti-
tudes. Also the use of neutral, precise and respectful (NPR) language may contribute (Scholten et al. 2017).
Economic barriers are not specific for controlled medications, but a more general problem related to 
pharmaceutical products. Yet some mechanisms may be specific for controlled medications: e.g. (state) 
monopolies for the distribution of some medications in some countries; and complex procedures to obtain 
licenses and import permits, making the marketing of a product expensive and commercially unattractive, 
in particular in smaller countries.
Although access to all classes of controlled medications mentioned above seems to be difficult around 
the world, research has been conducted almost exclusively on opioid medications, and in particular opioid 
analgesics. This is not surprising, because of opioid-specific barriers. Their existence can be demonstrated 
by comparing a study by Health Action International and one by the International Association for Hospice 
and Palliative Care. Without opioid-specific barriers, availability would be equal for opioid analgesics and 
non-opioid medications. However, from these studies, which used the same methodology, we may conclude 
that availability of opioid analgesics is one quarter to half that of non-opioid medications (Cameron et al. 
2009; Pastrana et al. 2017). As availability is a condition for accessibility, this shows that access to opioid 
medications is more difficult in many countries than access to other medications, including other classes of 
controlled medications such as benzodiazepines (Scholten et al. 2020).
Measuring Consumption and Its Adequacy
Non-benchmarking methods
Traditionally, WHO has considered opioid analgesic consumption as an indicator for access to pain manage-
ment (Gilson et al. 2013). Usually, morphine equivalents (ME) are used for this purpose. Furthermore, to be 
able to compare countries, it should be expressed on a per capita basis (Scholten 2013). 
Consumption data for narcotic drugs (i.e. those substances regulated under the Single Convention on 
Narcotic Drugs, e.g. opioid analgesics) are collected already for a long time. They are collected and published 
by INCB in their most elementary form: the absolute amount by country and by substance. INCB’s mandate 
is based on the Single Convention on Narcotic Drugs. It goes back to the 1930s, long before the Single 
Convention was enacted. At the time, INCB’s predecessor, the Permanent Narcotics Control Board, collected 
these statistics. All countries being a party to the Single Convention mandatory submit their annual nar-
cotic drugs consumption to INCB and therefore, the INCB is a reliable source for global consumption data. 
Annually in March each year, INCB publishes statistical data with a two years delay. Thus, in March 2020, 
statistics for 2018 became available (International Narcotics Control Board 2020).
In addition to the work of INCB, the former Pain and Policy Studies Group (PPSG) at Wisconsin University, 
Madison, WI, USA, built a global database on opioid analgesic consumption based on INCB data. Since the 
late 1990s it collected data for the most frequently used opioids, converted them into morphine equivalents 
per capita and published these on its website (Cleary and Maurer 2018). PPSG’s work did not extend to the 
assessment of adequacy. However, the distribution curve of consumption is typically a logarithmic curve 
with large differences between the lowest and the highest country and many countries at low levels with a 
few high developed countries at the higher levels (Seya et al. 2011; Duthey and Scholten 2014; Scholten et 
al. 2019; Scholten et al. 2020). Therefore, although it did not indicate a right level,’ the work of PPSG made 
it self-evident that there is a large number of countries with under consumption.
Benchmarking methods
ACM and AOC Index
If the measurement is intended to assess whether the level is adequate for the purpose of managing pain, a 
benchmark is essential and how such a benchmark was established should be documented. 
Adequacy of consumption has been calculated since 2006, first by WHO as the Access to Controlled 
Medicines Measure (ACM), then modified into the Adequacy of Opioid Consumption Index (AOC Index). 
Both ACM and AOC Index are based on the WHO Calculation Method for Drug Utilization Studies (Hogerzeil 
1986; Action Programme on Essential Drugs and Vaccines 1988; Seya et al. 2011; Duthey and Scholten 2014; 
Scholten et al. 2019; Scholten et al. 2020). In this method, the average per capita consumption of a number 
of well-performing countries (in this case the top 20 of the Human Development Index) is considered to be 
an adequate level. In the AOC Index, this level is represented by an index ≥ 100. Lower numbers represent a 
lower level of adequacy. There are several differences between the ACM and AOC Index methods, the most 
important being the ACM additionally including morbidity levels for three important conditions combined 
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with extrapolation to the need for all conditions with pain (Seya et al. 2011; Duthey and Scholten 2014). In 
the AOC Index, these morbidity statistics were abandoned because of the complexity of the procedures and 
problems obtaining reliable data (Scholten et al. 2019).
The WHO Calculation Method for Drug Utilization Studies was validated by studies by Hogerzeil (1986).
There is also some evidence from the Netherlands that this method applied in the form of the AOC Index 
is meaningful. A meta-analysis including studies from the Netherlands from 1995 to 2009 found that 43% 
of chronic non-cancer pain reported not to receive pain treatment and 79% of patients believed their 
pain is inadequately treated (Bekkering et al. 2011). This leaves 57% receiving pain treatment and 21% of 
patients considering the pain to be treated adequately, while the ACM for 2006 was 51% adequacy for the 
Netherlands (Seya et al. 2011). Thus, figures found by Bekkering (2001) and by Seya et al. (2011) correspond 
quite accurately.
When testing quality indicators for pharmaceutical care at the Amsterdam Academic Medical Center from 
April to June 2009, De Boer et al. (2014) found that only 41% of the patients were treated in compliance 
with the norm (‘IF the pain score is 4 or higher, THEN the pain medication needs to be adapted in order to 
lower the pain score’) while the ACM for 2010 for the Netherlands was 45% adequacy (Duthey and Scholten 
2014). These findings correspond very well.
Both examples show support for considering an AOC Index ≥ 100 as a norm for adequate pain treatment. 
Moreover, it was demonstrated that the adequate level calculated by means of the AOC Index is not very 
sensitive for disturbances. 
The application of the AOC Index is only suitable for use in the general population, because the data on 
which they are based stem from general populations of countries word wide. It is a coarse measure and 
therefore suitable to assess adequacy levels in countries with a lower level of adequacy. In case that a country 
is approaching adequate levels, the authors recommend further finetuning of policies by direct measure-
ment of pain levels, i.e. using pain surveys (Scholten 2020). Such surveys will also enable to identify situa-
tions where under treatment and over treatment exist simultaneously.
Global levels of adequacy of consumption for 2015, expressed as the AOC Index, are presented as a world 
map in Figure 1.
The Lancet Commission for Palliative Care and Pain Relief
Another approach to assess adequacy of opioid analgesic consumption is the approach by the Lancet Com-
mission for Palliative Care and Pain Relief. The Lancet Commission compared actual consumption with 
the need for opioid analgesics for 20 health conditions. Calculations were based on the three year average 
acquisition of opioids by country over the years 2011–2013. The need for pain treatment from each of these 
20 diseases was calculated using the amount of morphine needed per patient per day, the average duration 
of the disease and the total number of patients. Then it was totalized. The amounts of morphine needed 
and the average durations were defined by one clinician. For Western European countries the benchmark is 
established using a different method, selectively leaving out a large number of outliers. The publications by 
the Lancet Commission do not provide external proof of evidence for this benchmark, and neither do they 
mention the source of disease prevalence statistics used. More recently, Lancet Commission’s approach was 
endorsed by the International Association on Hospice and Palliative Care (Knaul et al. 2017; Global Data 
Platform to Calculate SHS and Palliative Care Need 2018). 
Comparing the AOC Index to the Lancet Commission’s benchmark shows a range of approximately 4.5–
36.7 times difference (depending on the country) between the two benchmarks, the latter being the lower. A 
separate benchmark was established for industrialised countries, using a different methodology. The Lancet 
Commission stated that consumption in most western European Countries, the USA, Canada, and Australia 
is at or well above need (Knaul et al. 2018). E.g., for Canada a consumption is reported which is 31 times 
higher than needed, for the Netherlands it is 9 times and for Germany it is 15 times (Global Data Platform to 
Calculate SHS and Palliative Care Need 2018).
INCB
A third approach is the INCB approach (which stands separate from its annual statistical reports). INCB 
used an upper limit of 200 S-DDD (Statistical Defined Daily Doses) per million inhabitants per day for ‘inad-
equate use’ and 100 S-DDD per million inhabitants per day1 for ‘very inadequate use’ (Berterame et al. 2016; 
 1 200 S-DDD per million inhabitants per day is equivalent to 7.3 mg Morphine equivalent per capita per year. 
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International Narcotics Control Board 2016). This benchmark corresponds to AOC Indices of 1.4 and 2.9, 
which represent ‘extremely low consumption.’ It is 34 times lower than the benchmark of the AOC Index. 
The publication does not provide an explanation why these benchmarks are chosen and how. It is also not 
explained whether > 200 S-DDD means that consumption is adequate. In newer publications however, the 
INCB abandoned this approach and reported consumption levels only, without relating these levels to levels 
of adequacy (International Narcotics Control Board 2019).
Current Trends in Consumption
General
The INCB has been warning for a too low consumption since 1989 (International Narcotics Control Board 
1989). Then, over time, the total global consumption increased, mainly caused by the increase of the per 
capita consumption in many industrialised countries. In many developing countries, there is also improve-
ment, but usually on a too small scale for overcoming under treatment substantially. In the latter countries, 
improvement did not keep pace with the former. Between 2000 and 2015, the gap between high and low 
developed countries even widened (Scholten et al. 2020). 
The American Crisis of opioid-induced Death
In the United States of America, there is a ‘national epidemic’ ongoing of high numbers of lethal intoxica-
tions from opioids. It is a continuation of the epidemic that started already after the Vietnam War in the 
early 1970s, when it manifested as heroin use disorder. This epidemic was never gone, but changed to the 
use of opioid medications (mainly oxycodone) around the year 2000 and became more serious rapidly. Then, 
it changed to fentanyl derivatives from illicit sources in recent years.
These developments in the USA attracted worldwide attention in the past years and will affect access to 
opioid medications in many other countries. A few aspects of this epidemic, which are relevant for the inter-
national situation, are highlighted here.
For a long time already, it was doubtful that opioids causing accidental death in the United States origi-
nated from medications prescribed to pain patients. However, insurance companies, politicians and authori-
ties, including the USA Centers for Disease Control (CDC) and the Drug Enforcement Administration have 
been blaming pain patients and their prescribers for causing the crisis. They did not distinguish between 
actually prescribed medications and medications intended for prescription, and also not between the medi-
cation fentanyl, illicitly produced fentanyl, and its more potent illicit derivatives (‘fentanils’), of which many 
do not have any medical or veterinary use and which are only available on the illicit markets. Because 
the mechanisms behind the many lethal opioid intoxications in the United States were not well analysed, 
Figure 1: Country levels of adequacy of per capita opioid analgesic consumption, 2015. Levels of adequacy: 
dark blue: adequate (Adequacy of Opioid Consumption Index ≥100); light blue: moderate (AOC Index ≥30 
and <100); orange: low (AOC Index ≤10 and <30); light red: very low (AOC Index ≥3 and <10); dark red: 
extremely low consumption (AOC Index <3); grey: no data available. (From: Scholten et al. 2019b; https://
www.tandfonline.com/).
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the responses were also not an answer to the problems and therefore, cannot revert these (Scholten and 
Henningfield 2016a; Scholten and Henningfield 2016b; Dasgupta, Beletsky and Ciccarone 2018).
Because of this, pain patients were gradually denied access to opioid pain relievers. The amount of opioids 
prescribed in the United States, dropped from 782 mg ME in 2010 to 640 mg ME per capita in 2015 (Guy et 
al. 2017), but the number of deaths increased with 57% over the same period (National Center on Health 
Statistics - CDC Wonder no date). In the United States, large numbers of people with pain saw their dosages 
involuntary reduced without individual assessment (Weeks 2016; Samet and Kertesz 2018), and as a result 
many people with pain complain that their pain is not properly addressed any more, even to such an extent 
that Human Rights Watch announced to investigate the United States for torture with this respect (Anson 
2018). 
Finally, it was recognized by the CDC that the epidemic is not driven by opioids prescribed to pain 
patients (O’Donnell et al. 2017). Moreover, the CDC admitted in 2016, that they have historically catego-
rized ‘all opioid pain reliever deaths (natural and semisynthetic opioids, methadone, and other synthetic 
opioids, regardless whether they originate from licit or illicit sources) as “prescription opioid overdoses”’ 
(Rudd et al. 2016). However, a recent study showed that only 1.3% of those who died from an opioid intoxi-
cation in Massachusetts had an active prescription for each opioid detected in toxicology reports on the 
date of death (Walley et al. 2019). An analysis of data from southwest Virginia from between 2011 and 
2015 demonstrated that of patients with cancer to whom opioid analgesics were prescribed in this rural 
and medically underserved area, less than 10 out of 652 experienced opioid use disorder–related hospi-
talizations. At the same time data suggested under treatment of cancer-related pain among these patients 
(LeBaron et al. 2019). 
Effect on other Countries
The situation in the United Stated has much been conflated by erroneous data. For instance, the Centers for 
Disease Control and the anti-opioid organisation Physicians for Responsible Prescribing reported that the US 
per capita consumption of opioid analgesics is 1.7–4.1 times higher than the actual consumption reported 
officially by the US Drug Enforcement Administration to the INCB (Scholten and Henningfield 2016a). Such 
dramatic data did not remain unremarked in other countries. Pressure on the World Health Organization 
after false allegations from the US side that the content of a treatment guideline and a policy guideline were 
influenced by the pharmaceutical industry, lead to the withdrawal of these guidelines (Anson 2019). 
Gradually, the USA debate has developed a ‘spill-over’ effect to regulatory authorities in Europe and in 
developing countries, contributing to restrictions in opioid availability, even though most of these countries 
do not experience problems with prescribed opioid analgesics. 
American authors recommended to limit access to opioid analgesics in other countries, e.g. in the European 
Union and in Saudi Arabia (Martins and Ghandour 2017), in spite that opioid analgesic usage in Saudi Arabia 
is already low (AOC Index2015: 16) (Scholten et al. 2020). Moreover, problems reported on opioid use in the 
European Union are rarely related to pain treatment (Scholten 2017; European Drug Report 2019, Trends 
and developments 2019). Non-medical use of opioids mainly relates to heroin (around 78%), followed by 
methadone and buprenorphine (together 14%; usually used in AOT and rarely for pain treatment). Germany 
has the highest per capita consumption of opioid analgesics in the world, but without serious opioid use 
problems being reported (Häuser, Schug and Furlan 2017).
Europe has better access to opioid agonist therapy (OAT) which is the first choice treatment for opioid use 
disorder recommended by WHO (World Health Organization 2009). Therefore, Europe is better prepared for 
potential substance use problems than the USA is. In 2009, the USA had a coverage for OAT of only 13 out 
of every 100 people who inject drugs (Mathers et al. 2010). In 2014, nearly 80% of individuals with an opi-
oid use disorder did not receive treatment in the USA (SAMHSA 2017). From the 22 EU countries with data 
available, the median coverage (calculated as OAT clients/number of high-risk opioid users) is 47% (range 
8–86%) (based on data from the European Drug Report 2019 Package, Country reports 2019). 
Discussion
Measurement of opioid analgesic consumption is an important tool for defining public-health policies 
aimed at improving pain management. As shown above, measurement started long ago with the collection 
of absolute consumption data by the Permanent Narcotics Control Board. Later on, its successor INCB drew 
attention to the under treatment of pain; the PPSG refined the available data into per capita statistics in an 
easily accessible online database. However, for adjusting policies, it is better to compare with a standard, 
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because only this provides an indication of the required direction of change. Scholten and collaborators, the 
INCB and the Lancet Commission, each developed a benchmark, but in different ways, and with very differ-
ent outcomes. 
When using a benchmark, the method used to establish it should be transparent. 
INCB does not provide any explanation for the benchmark it used in the past. It is an extremely low bench-
mark, and therefore does not effectively contribute to improving access, and rather maintains the status 
quo. It may provide somewhat help only to those countries where access is almost non-existent. It looks like 
a compromise was negotiated between INCB members willing to improve access to controlled medications 
and those who were against. This seems to be less the case with the current composition of INCB, and this 
may be the reason that in newer publications this benchmark silently disappeared.
The benchmark established by the Lancet Commission on Palliative Care and Pain Relief is a calculated 
benchmark, using a selection of 20 important conditions that require pain relief, but therefore, also exclud-
ing so many other conditions that come with pain. This causes a systematic error leading to under reporting. 
This comes on top of the known under reporting in any health statistics. A correction for need for pain relief 
for the missing conditions is not applied. Moreover, using a separate benchmark for industrialised countries, 
developed through exclusion of many outliers is not scientific. The conclusions by the Lancet Commission 
that quite a number of countries with well-functioning health systems have over consumption up to 310 
times feels awkward and does not contribute to its credibility. 
The AOC Index has some indirect evidence that its benchmark lies in the correct order of magnitude, but 
also this benchmark is not fully validated. All methods need further validation, but validation may be hard. 
It has no morbidity correction after this correction was abolished when the ACM was replaced by the AOC 
Index. Reasons were the relative unreliability and limited availability of the statistics used. 
Looking at the strengths of the ACM, the AOC Index and the Lancet Commission methods, an ideal 
method would use a benchmark composed of the need from 20 diseases from the latter method followed 
by extrapolation to the need for all diseases as applied in the ACM. Simultaneously, this extrapolation could 
correct for under reporting health statistics. Like for the AOC Index and the Lancet Commission’s method, 
full adequacy could be expressed as ‘100’ of ‘100%.’ Methods, data sources and tables with results should be 
publicly accessible like in the ACM and the AOC Index, with supplementary graphs and maps. 
Access to controlled medications such as opioid analgesics has been problematic for a long time and many 
influences contribute to the continuation or the return of inadequate access. One such an influence is the 
false narrative that pain patients are the underlying cause of lethal opioid intoxications in the USA, and the 
resulting fear that this will spread to European countries. Unfortunately, politicians, health-care insurers 
and the press hold and promote strong opinions contradictory to scientific evidence. This is not only the 
case in the USA, but more and more in some European countries too. Today, in many countries, the absolute 
per capita consumption of opioid analgesics is rather going down than up. This coincides with increasing 
numbers of people suffering moderate to severe pain, whose pain is not or under treated.
Less informed advocates started lobbying against the use of opioids in several countries, including the 
author’s own country, the Netherlands. Measures for a reduction were announced in the Netherlands. Such 
unbalanced policy responses may in the long–term lead to under treatment of moderate and severe pain. 
Globally, opioid analgesics will remain a corner stone of pharmacological pain management, ideally as an 
element of a multimodal therapeutic approach (using less opioids by combining pharmacological and non-
pharmacological pain treatment options, leading to lower opioid consumption). To avoid that prescribed 
opioids will be used in inappropriate and harmful ways, prescribing them should always be considerate 
(Fanelli et al. 2016; Scholten and Henningfield 2016a). However, considerate prescribing becomes unethical 
when it means withholding treatment to people with moderate and severe pain.
Though in modern anaesthesiology a multi-modal approach is considered the ideal approach, we need to 
realize that pain is omnipresent in both developing and industrialised countries where many suffer chronic 
pain. It is not realistic to aim at all these people being treated by anaesthesiologists; the large majority will 
be treated by generalists. However, as long as the current under education on pain treatment persists in the 
general medical curriculum, it is unlikely that general practitioners will be able to provide much more than 
just pharmacological treatment.
The question is also what the effect will be of the current COVID-19 pandemic on future access policies 
related to controlled medications. In recent months, it has become evident that palliative care can provide 
considerable relief to COVID-19 patients in ICUs, but this will require substances like opioid analgesics and 
midazolam to be readily available. 
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The World Health Assembly called on the WHO Member States in a resolution on the response to COVID-
19 inter alia to provide access to palliative care (World Health Assembly 2020). We may hope that this will be 
an occasion for policy makers to realise the importance of controlled medicines for treating large numbers 
of patients with limited staffing. 
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